DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A

被引:143
作者
Coelmont, Lotte [1 ]
Hanoulle, Xavier [2 ]
Chatterji, Udayan [3 ]
Berger, Carola [4 ]
Snoeck, Joke [1 ]
Bobardt, Michael [3 ]
Lim, Precious [3 ]
Vliegen, Inge [1 ]
Paeshuyse, Jan [1 ]
Vuagniaux, Gregoire [5 ]
Vandamme, Anne-Mieke [1 ]
Bartenschlager, Ralf [4 ]
Gallay, Philippe [3 ]
Lippens, Guy [2 ]
Neyts, Johan [1 ]
机构
[1] Katholieke Univ Leuven, Dept Microbiol & Immunol, Rega Inst Med Res, Louvain, Belgium
[2] Univ Lille 1, Ctr Natl Rech Sci, Unite Mixte Rech 8576, F-59655 Villeneuve Dascq, France
[3] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA
[4] Heidelberg Univ, Dept Mol Virol, Heidelberg, Germany
[5] Debiopharm, Pharmacol & Screening Unit, Lausanne, Switzerland
来源
PLOS ONE | 2010年 / 5卷 / 10期
关键词
NONSTRUCTURAL PROTEIN 5A; CYCLOSPORINE-A; ISOMERASE ACTIVITY; RNA REPLICATION; RESISTANCE; BINDING; DEBIO-025; IDENTIFICATION; COMBINATION; POLYMERASE;
D O I
10.1371/journal.pone.0013687
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
DEB025/Debio 025 (Alisporivir) is a cyclophilin (Cyp)-binding molecule with potent anti-hepatitis C virus (HCV) activity both in vitro and in vivo. It is currently being evaluated in phase II clinical trials. DEB025 binds to CypA, a peptidyl-prolyl cis-trans isomerase which is a crucial cofactor for HCV replication. Here we report that it was very difficult to select resistant replicons (genotype 1b) to DEB025, requiring an average of 20 weeks (four independent experiments), compared to the typically <2 weeks with protease or polymerase inhibitors. This indicates a high genetic barrier to resistance for DEB025. Mutation D320E in NS5A was the only mutation consistently selected in the replicon genome. This mutation alone conferred a low-level (3.9-fold) resistance. Replacing the NS5A gene (but not the NS5B gene) from the wild type (WT) genome with the corresponding sequence from the DEB025(res) replicon resulted in transfer of resistance. Cross-resistance with cyclosporine A (CsA) was observed, whereas NS3 protease and NS5B polymerase inhibitors retained WT-activity against DEB025(res) replicons. Unlike WT, DEB025(res) replicon replicated efficiently in CypA knock down cells. However, DEB025 disrupted the interaction between CypA and NS5A regardless of whether the NS5A protein was derived from WT or DEB025(res) replicon. NMR titration experiments with peptides derived from the WT or the DEB025(res) domain II of NS5A corroborated this observation in a quantitative manner. Interestingly, comparative NMR studies on two 20-mer NS5A peptides that contain D320 or E320 revealed a shift in population between the major and minor conformers. These data suggest that D320E conferred low-level resistance to DEB025 probably by reducing the need for CypA-dependent isomerisation of NS5A. Prolonged DEB025 treatment and multiple genotypic changes may be necessary to generate significant resistance to DEB025, underlying the high barrier to resistance.
引用
收藏
页数:14
相关论文
共 54 条
  • [21] Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics
    Kaul, Artur
    Stauffer, Sarah
    Berger, Carola
    Pertel, Thomas
    Schmitt, Jennifer
    Kallis, Stephanie
    Lopez, Margarita Zayas
    Lohmann, Volker
    Luban, Jeremy
    Bartenschlager, Ralf
    [J]. PLOS PATHOGENS, 2009, 5 (08)
  • [22] Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses
    Koutsoudakis, George
    Kaul, Artur
    Steinmann, Eike
    Kallis, Stephanie
    Lohmann, Volker
    Pietschmann, Thomas
    Bartenschlager, Ralf
    [J]. JOURNAL OF VIROLOGY, 2006, 80 (11) : 5308 - 5320
  • [23] Structural Basis for the Non-Immunosuppressive Character of the Cyclosporin A Analogue Debio 025
    Landrieu, Isabelle
    Hanoulle, Xavier
    Bonachera, Fanny
    Hamel, Arnaud
    Sibille, Nathalie
    Yin, Yanxia
    Wieruszeski, Jean-Michel
    Horvath, Dragos
    Wei, Qun
    Vuagniaux, Gregoire
    Lippens, Guy
    [J]. BIOCHEMISTRY, 2010, 49 (22) : 4679 - 4686
  • [24] Identification of Hepatitis C Virus NS5A Inhibitors
    Lemm, Julie A.
    O'Boyle, Donald, II
    Liu, Mengping
    Nower, Peter T.
    Colonno, Richard
    Deshpande, Milind S.
    Snyder, Lawrence B.
    Martin, Scott W.
    Laurent, Denis R. St.
    Serrano-Wu, Michael H.
    Romine, Jeffrey L.
    Meanwell, Nicholas A.
    Gao, Min
    [J]. JOURNAL OF VIROLOGY, 2010, 84 (01) : 482 - 491
  • [25] Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded
    Liang, Yu
    Ye, Hong
    Kang, Cong Bao
    Yoon, Ho Sup
    [J]. BIOCHEMISTRY, 2007, 46 (41) : 11550 - 11558
  • [26] Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex
    Liu, Zhe
    Yang, Feng
    Robotham, Jason M.
    Tang, Hengli
    [J]. JOURNAL OF VIROLOGY, 2009, 83 (13) : 6554 - 6565
  • [27] Mutations in the Hepatitis C Virus Polymerase that Increase RNA Binding Can Confer Resistance to Cyclosporine A
    Liu, Zhe
    Robida, John M.
    Chinnaswamy, Sreedhar
    Yi, Guanghui
    Robotham, Jason M.
    Nelson, Heather B.
    Irsigler, Andre
    Kao, C. Cheng
    Tang, Hengli
    [J]. HEPATOLOGY, 2009, 50 (01) : 25 - 33
  • [28] Mutations in hepatitis C virus RNAs conferring cell culture adaptation
    Lohmann, V
    Körner, F
    Dobierzewska, A
    Bartenschlager, R
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (03) : 1437 - 1449
  • [29] Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line
    Lohmann, V
    Körner, F
    Koch, JO
    Herian, U
    Theilmann, L
    Bartenschlager, R
    [J]. SCIENCE, 1999, 285 (5424) : 110 - 113
  • [30] NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon
    Ma, Sue
    Boerner, Joanna E.
    TiongYip, ChoiLai
    Weidmann, Beat
    Ryder, Neil S.
    Cooreman, Michael P.
    Lin, Kai
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (09) : 2976 - 2982